Advanced BioScience Laboratories, Inc. Awards Avid Bioservices, Inc. HIV Vaccine Development and Manufacturing Contract
Published: Sep 27, 2012
TUSTIN, CA, and ROCKVILLE, MD--(Marketwire - September 27, 2012) - Avid Bioservices, a subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today announced that it has been chosen by Advanced BioScience Laboratories, Inc. (ABL) to provide development and large-scale manufacturing services to support cGMP production of an HIV envelope protein, as a component of a preventive vaccine against HIV infection. ABL recently received funding from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to provide preclinical development and cGMP manufacturing support for multiple vaccine and biologic products, of which this project is included.
Under the terms of the contract, Avid will provide services from process verification and assay development through to development of a robust and compliant process for large-scale manufacturing, to support cGMP production of the gp145 HIV envelope protein. Other terms of the contract were not disclosed.
"This partnership represents our shared commitment to providing patients worldwide with better HIV prevention options and ABL is looking forward to working with Avid to advance this NIH program forward," said Dr. Thomas VanCott, president & chief executive officer at ABL. "Avid has established experience and expertise that we feel will be a great complement to the existing processes for this application."
"We are pleased that our manufacturing capabilities have been chosen to support this important project and contribute to a major health issue that impacts the global stage," said Steven W. King, president of Avid Bioservices. "HIV continues to be an epidemic for which more prevention strategies are needed and we are enthusiastic about working toward a potential solution in collaboration with ABL and the NIH."
This project has been funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201100021I.
About Avid Bioservices
Avid Bioservices provides a comprehensive range of high quality cGMP manufacturing services for the biotechnology and biopharmaceutical industries to support manufacturing of cGMP commercial and clinical products. With over 10 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include stability testing, clinical and commercial product manufacturing and purification, bulk packaging, final product filling and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line optimization, analytical methods development and product characterization. For more information about Avid, please visit www.avidbio.com.
Advanced BioScience Laboratories, Inc. (ABL) is a Maryland-based biomedical contract research and manufacturing organization dedicated to advancing the development of therapeutics, vaccines and other biologic products. ABL has extensive experience working with diverse organizations, including government and academic entities and commercial bio/pharmaceutical companies. Notable services include basic research, product design, process and assay development, preclinical in vivo and in vitro studies (including immunomonitoring), and Phase I/II cGMP biologics manufacturing. Since 2001 ABL has been a part of the Institut Mérieux, a group of companies dedicated to developing translational science for better patient care globally. For more information on ABL and our services, please visit our website at www.ablinc.com.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, conducts and supports research -- at NIH, throughout the United States, and worldwide -- to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. For more information, visit http://www.niaid.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
Chris Keenan or Kelly Lord